The AAN and the triple aim The American Academy of Neurology (AAN) has long been a leader among medical professional societies in being dedicated to providing tools aimed at improving the quality of neurologic care. Since the emergence of a Federal call for evidence-based guidelines in the early 1990s, AAN subcommittees have produced almost 200 guidelines using the most stringent systematic review methods. More recently, other AAN subcommittees translated some of our guidelines into quality indicators for several neurologic disorders (e.g., epilepsy, Parkinson disease, amyotrophic lateral sclerosis, distal symmetrical neuropathy). This set of tools is aimed at helping neurologists in ambulatory care settings improve quality, which should, if well-implemented, lead to improved health outcomes.
Since the passage of the Affordable Care Act, the policy and payment environment changed dramatically in an effort to reduce out-of-control health care cost inflation and provide the highest value health care. The Centers for Medicare & Medicaid Services (CMS) led the way. Billions of dollars are being invested in grants to deliver accountable care with the triple aim of improving the quality and experience of care for individuals, improving the health of populations, and reducing per capita costs of health care.
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The emphasis is on care and payment models that reward achieving the aims, redesign of health systems, and deemphasizing fee-for-service payments.
So, where does neurology fit into all of this? Will we allow these fundamental policy shifts to overcome us like a tsunami, or can we rise to the challenge and define quality and demonstrate the value of neurologic care? The Medicare Access and CHIP Reauthorization Act of 2015 led CMS to a proposed rule that provides a detailed roadmap for Medicare's transition from volume-to value-based payments. 3 It includes provisions for qualified clinical data registries to define a specialty's quality metrics that are recognized by CMS's Physician Quality Reporting System and Merit-based Incentive Payment System (MIPS) programs. Our specialty would be wise to understand and follow this roadmap. Other payers are likely to follow Medicare's lead.
Leaders in our field anticipated these changes and provided some guidance for a path forward for academic neurology and practicing neurologists. [4] [5] [6] Besides the AAN's guidelines and quality indicators, what else can the AAN, or the practicing neurologist, do to simultaneously maintain our essential viability as a specialty and contribute to the national effort? Sigsbee et al., 7 in this issue of Neurology ® , describe a third AAN quality initiative: the development of a clinical quality data registry, the Axon Registry. The effort, more fully described on the AAN Web site, is well underway. 8 The main goal is to capture metrics of data quality and outcomes in ambulatory care practice. The registry will be pilot testing about 15 quality indicators with volunteer partners. Questions regarding data security, Health Insurance Portability and Accountability Act compliance, and data use agreements have been addressed. 8 There is a central cloudbased server overseen by the AAN via a vendor, and data would be entered, to the extent possible, via automatic data capture methods from existing electronic health records (EHRs). These data could theoretically be used, for example, to justify incentive-based payments (e.g., from the future CMS MIPS) and for maintenance of certification.
Sigsbee et al. 7 also discuss quality improvement efforts in general, but in-depth information as to how exactly a clinical data registry run by a specialty society would be worth the effort and cost is not presented. Other articles are planned to address details of implementation and more specific goals.
We should plan how to overcome the challenges faced by other medical societies in implementing their registries. For our registry to be a success, we need to (1) overcome the lack of interoperability among EHRs that can impede data entry into the registry; (2) ensure the data we acquire is desired by important policymakers and payers, including outcomes measures, patient satisfaction measures, and resource use; (3) persuade large health care organizations to participate in the registry; and (4) determine how to pay for ongoing registry maintenance and development.
Saper 5 pointed out that ambulatory care neurology is in a much different position than primary care, where every other patient may have a condition worthy of implementing a quality indicator metric. Unless at least some of the emphasis of our clinical data registry is on the more common conditions with a substantial population health burden, such as musculoskeletal pain, 9 it may be difficult to engage Federal policymakers successfully.
Registries focused on more acute conditions or intervention-based procedures have proven their worth. The Get With The Guidelines-Stroke collaborative among 790 volunteer US academic and community hospitals demonstrated major improvement in adherence to all stroke performance measures. 10 However, methodologic differences among registries can lead to substantial differences in reporting of comorbidities or adverse events. 11 Relying on volunteer organization-based registries may thus lead to conclusions that are not generalizable enough to influence payment policy. Data registries that can be linked to administrative databases are more likely to fulfill goals related to the conduct of relevant comparative effectiveness outcomes research, another high-priority goal of the Federal government 12 and the AAN. The AAN estimates that the demand for neurologists far exceeds the current and future supply. Recently emerging subspecialty areas, such as neurointensivists, neurohospitalists, and neurointerventionalists, offer important types of neurologic care that were previously unavailable. But in order to help meet our nation's health care goals, we cannot be insular-we need to be much more engaged in an interdisciplinary health care team. We should develop methods to solve problems we have not previously addressed, such as reducing avoidable hospital readmissions, preventing disability from low back pain, and other strategic goals that are crucial to achieving the triple aim.
A quality improvement roadmap for inpatient neurologic conditions has been proposed. 13 We look forward to further progress and a similar evidencebased roadmap for the AAN's Axon Registry.
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